{"id":"https://openalex.org/W2099550296","doi":"https://doi.org/10.1007/s00280-014-2576-8","title":"A first-in-human study of the anti-\u03b15\u03b21 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors","display_name":"A first-in-human study of the anti-\u03b15\u03b21 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors","publication_year":2014,"publication_date":"2014-09-11","ids":{"openalex":"https://openalex.org/W2099550296","doi":"https://doi.org/10.1007/s00280-014-2576-8","mag":"2099550296","pmid":"https://pubmed.ncbi.nlm.nih.gov/25212537","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4209234"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-014-2576-8","doi":"https://doi.org/10.1007/s00280-014-2576-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2576-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2576-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2576-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037380661","display_name":"Joaqu\u0131\u0301n Mateo","orcid":"https://orcid.org/0000-0001-5336-2548","observed_orcids":["https://orcid.org/0000-0001-5336-2548"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Mateo","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039492614","display_name":"Jordan D. Berlin","orcid":"https://orcid.org/0000-0001-7571-2385","observed_orcids":["https://orcid.org/0000-0001-7571-2385"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Berlin","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN, USA","Vanderbilt-Ingram Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]},{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. S. de Bono","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110382646","display_name":"Roger B. Cohen","orcid":"https://orcid.org/0009-0004-7423-2653","observed_orcids":["https://orcid.org/0009-0004-7423-2653"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. B. Cohen","raw_affiliation_strings":["Developmental Therapeutics Program and Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA","Fox Chase Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Program and Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA","institution_ids":["https://openalex.org/I1289437631"]},{"raw_affiliation_string":"Fox Chase Cancer Center","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087055974","display_name":"Vicki Leigh Keedy","orcid":"https://orcid.org/0000-0002-7213-7562","observed_orcids":["https://orcid.org/0000-0002-7213-7562"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. Keedy","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN, USA","Vanderbilt-Ingram Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]},{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028906255","display_name":"Ganesh M. Mugundu","orcid":"https://orcid.org/0000-0002-3736-1884","observed_orcids":["https://orcid.org/0000-0002-3736-1884"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Mugundu","raw_affiliation_strings":["Pfizer Oncology, La Jolla, CA, USA","Pfizer- Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer- Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091864599","display_name":"Lianglin Zhang","orcid":"https://orcid.org/0009-0009-7781-3118","observed_orcids":["https://orcid.org/0009-0009-7781-3118"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lianglin Zhang","raw_affiliation_strings":["Pfizer Oncology, La Jolla, CA, USA","Pfizer- Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer- Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055636076","display_name":"Antonello Abbattista","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Abbattista","raw_affiliation_strings":["Pfizer Oncology, Groton, CT, USA","Pfizer- Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer- Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072398101","display_name":"Craig B. Davis","orcid":"https://orcid.org/0000-0002-1703-451X","observed_orcids":["https://orcid.org/0000-0002-1703-451X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Davis","raw_affiliation_strings":["Pfizer Oncology, Groton, CT, USA","Pfizer- Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer- Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031901871","display_name":"Corrado Gallo Stampino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Gallo Stampino","raw_affiliation_strings":["Pfizer Oncology, Groton, CT, USA","Pfizer- Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer- Oncology","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012061864","display_name":"Hossein Borghaei","orcid":"https://orcid.org/0000-0002-2577-4454","observed_orcids":["https://orcid.org/0000-0002-2577-4454"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"H. Borghaei","raw_affiliation_strings":["Developmental Therapeutics Program and Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA","Fox Chase Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Program and Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA","institution_ids":["https://openalex.org/I1289437631"]},{"raw_affiliation_string":"Fox Chase Cancer Center","institution_ids":["https://openalex.org/I1289437631"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5012061864"],"corresponding_institution_ids":["https://openalex.org/I1289437631"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":4.3319,"has_fulltext":true,"cited_by_count":35,"citation_normalized_percentile":{"value":0.94452214,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"74","issue":"5","first_page":"1039","last_page":"1046"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":0.8080999851226807,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":0.8080999851226807,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.1680999994277954,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.014499999582767487,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/integrin-alpha5beta1","display_name":"alpha5beta1 integrin","score":0.953000009059906},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9089999794960022},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7609999775886536},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.718999981880188},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.7990000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9300000071525574},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9079999923706055},{"id":"https://openalex.org/keywords/clinical-trial-termination","display_name":"clinical trial termination","score":0.5019999742507935}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8252388834953308},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7427825927734375},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7087154388427734},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6533472537994385},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5673966407775879},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5632324814796448},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5612363815307617},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5216946005821228},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5094512104988098},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4558592438697815},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4359409213066101},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4301050305366516},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4001055359840393},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38934314250946045},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33228015899658203},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.30570703744888306},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23270359635353088}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005483","descriptor_name":"Flushing","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007022","descriptor_name":"Hypotension","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D039081","descriptor_name":"Integrin alpha5beta1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s00280-014-2576-8","doi":"https://doi.org/10.1007/s00280-014-2576-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2576-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2576-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4209234","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4209234","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemother Pharmacol","raw_type":"Text"},{"id":"pmid:25212537","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25212537","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1007/s00280-014-2576-8","doi":"https://doi.org/10.1007/s00280-014-2576-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-014-2576-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-014-2576-8.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2099550296.pdf","grobid_xml":"https://content.openalex.org/works/W2099550296.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1576773659","https://openalex.org/W1884786349","https://openalex.org/W1905978178","https://openalex.org/W1915689252","https://openalex.org/W1980184027","https://openalex.org/W1983426119","https://openalex.org/W2000845191","https://openalex.org/W2026184890","https://openalex.org/W2038413195","https://openalex.org/W2046829035","https://openalex.org/W2048164597","https://openalex.org/W2066665315","https://openalex.org/W2077090481","https://openalex.org/W2088056286","https://openalex.org/W2099145932","https://openalex.org/W2101824720","https://openalex.org/W2109638333","https://openalex.org/W2111261737","https://openalex.org/W2112887207","https://openalex.org/W2113182862","https://openalex.org/W2114463465","https://openalex.org/W2115759102","https://openalex.org/W2125382736","https://openalex.org/W2128402413","https://openalex.org/W2129021355","https://openalex.org/W2132661000"],"related_works":["https://openalex.org/W7098957113","https://openalex.org/W2015177736","https://openalex.org/W2046829035","https://openalex.org/W2312230075","https://openalex.org/W2026184890","https://openalex.org/W2057067749","https://openalex.org/W2570141822","https://openalex.org/W4399319890","https://openalex.org/W1970267589","https://openalex.org/W2247505779"],"abstract_inverted_index":{"PURPOSE:":[0],"A":[1],"first-in-human":[2],"clinical":[3,225],"trial":[4,213],"of":[5,33,109,183,205,227],"a":[6,66,219],"fully":[7],"human,":[8],"Fc-engineered":[9],"IgG1":[10],"monoclonal":[11],"antibody":[12],"targeting":[13],"integrin":[14],"\u03b15\u03b21":[15],"was":[16,76,146,169,214],"conducted":[17],"to":[18,47,88,121,196],"evaluate":[19],"tolerability,":[20],"maximum":[21,111,221],"tolerated":[22,112,151,222],"dose,":[23],"pharmacokinetics,":[24],"pharmacodynamics":[25],"and":[26,42,97,153,202],"preliminary":[27],"anti-tumor":[28,167,206],"activity.":[29],"METHODS:":[30],"Escalating":[31],"doses":[32,152,158,210],"PF-04605412":[34,228],"were":[35,62,86,102],"given":[36],"IV":[37],"on":[38,65,80,143,173,198],"day":[39],"1,":[40],"28":[41],"every":[43],"2":[44],"weeks":[45],"thereafter":[46],"patients":[48,85,101,115],"with":[49,180],"advanced":[50],"solid":[51],"tumors":[52],"until":[53],"disease":[54],"progression":[55],"or":[56],"unacceptable":[57],"toxicity.":[58],"Sequential":[59],"dose":[60,75,90,194],"cohorts":[61],"evaluated":[63],"based":[64,79,142],"modified":[67],"3":[68,70,129],"+":[69],"dose-escalation":[71],"design.":[72],"The":[73],"starting":[74],"7.5":[77],"mg":[78],"preclinical":[81,144],"data.":[82],"RESULTS:":[83],"Thirty-three":[84],"enrolled":[87],"six":[89],"levels":[91],"(7.5,":[92],"11.25,":[93],"16.9,":[94],"34,":[95],"68":[96],"136":[98],"mg).":[99],"Twenty-three":[100],"evaluable":[103],"for":[104],"the":[105,110,138,150,174,177,181,191,199,203,209,212],"primary":[106],"endpoint":[107],"(determination":[108],"dose).":[113],"Five":[114],"required":[116],"permanent":[117],"drug":[118,140],"discontinuation":[119],"due":[120],"acute":[122],"infusion-related":[123],"reactions,":[124],"which":[125],"occurred":[126],"as":[127],"grade":[128],"events":[130],"in":[131],"two":[132],"patients.":[133],"PK":[134,154],"analysis":[135],"indicated":[136],"that":[137,157],"targeted":[139],"exposure":[141],"models":[145],"not":[147],"achieved":[148],"by":[149],"modeling":[155],"suggesting":[156],"at":[159,188,208],"least":[160],"fivefold":[161],"higher":[162,189],"would":[163],"be":[164],"necessary.":[165],"No":[166],"activity":[168,207],"observed.":[170],"CONCLUSION:":[171],"Based":[172],"safety":[175],"data,":[176],"risks":[178],"associated":[179],"likelihood":[182],"significant":[184],"cytokine-mediated":[185],"infusion":[186],"reactions":[187],"doses,":[190],"projected":[192],"high":[193],"necessary":[195],"affect":[197],"biological":[200],"target":[201],"lack":[204],"explored,":[211],"prematurely":[215],"terminated":[216],"without":[217],"determining":[218],"formal":[220],"dose.":[223],"Further":[224],"development":[226],"has":[229],"been":[230],"discontinued.":[231]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}